Abstract
Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Current Pharmaceutical Design
Title:Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review
Volume: 23 Issue: 9
Author(s): Dimitrios A. Vrachatis*, Georgios Giannopoulos, Charalambos Kossyvakis, Vasiliki Panagopoulou, Manolis Vavuranakis, Theodore G. Papaioannou, Stamatina Pagoni, Vlasios N. Pyrgakis, Michael W. Cleman and Spyridon G. Deftereos
Affiliation:
- Department of Cardiology, “G. Gennimatas” General Hospital of Athens, 154 Mesogion ave., 115 27, Athens,Greece
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Abstract: Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Export Options
About this article
Cite this article as:
Vrachatis A. Dimitrios*, Giannopoulos Georgios, Kossyvakis Charalambos, Panagopoulou Vasiliki, Vavuranakis Manolis, Papaioannou G. Theodore, Pagoni Stamatina, Pyrgakis N. Vlasios, Cleman W. Michael and Deftereos G. Spyridon, Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161205115101
DOI https://dx.doi.org/10.2174/1381612822666161205115101 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms
Current Drug Targets Therapeutic Modulation of Growth Factors and Cytokines in Regenerative Medicine
Current Pharmaceutical Design Novel Oral Anticoagulants in the Management of Polycythemia Vera and Essential Thrombocythemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Factors Associated with Poor Hemoglobin A1c Control in Patients with Type 2 Diabetes
Current Diabetes Reviews Meet Our Editorial Board Member
Current Cardiology Reviews Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Safe Utilization of Hyperglycemia Management in the ICU
Current Drug Safety Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Development of Colon Specific Microspheres of Flurbiprofen for Inflammatory Bowel Disease
Current Drug Delivery Oral Supplements of <i>Ginkgo biloba</i> Extract Alleviate Neuroinflammation, Oxidative Impairments and Neurotoxicity in Rotenone-Induced Parkinsonian Rats
Current Pharmaceutical Biotechnology ADME Optimization and Toxicity Assessment in Early- and Late-Phase Drug Discovery
Current Topics in Medicinal Chemistry Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists
Cardiovascular & Hematological Disorders-Drug Targets Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Selective Matrix Metalloproteinase Inhibitors for Cancer
Current Medicinal Chemistry Positive Airway Pressure in Sleep Disordered Breathing
Current Respiratory Medicine Reviews The New Challenges of Brain PET Imaging Technology
Current Medical Imaging Effects of Remifentanil on the Cardiac Conduction System. Our Experience in the Study of Remifentanil Electrophysiological Properties
Current Pharmaceutical Design New Trends of Deep Learning in Clinical Cardiology
Current Bioinformatics